芍药苷治疗糖尿病及其并发症研究机制进展
Advancements in the Research Mechanisms of Paeoniflorin for the Treatment of Diabetes Mellitus and Its Complications
DOI: 10.12677/tcm.2025.148499, PDF,    科研立项经费支持
作者: 杨云姣, 陈 秋*：成都中医药大学附属医院内分泌科，四川 成都
关键词: 芍药苷；糖尿病；糖尿病并发症；抗炎；抗氧化；机制；Paeoniflorin； Diabetes Mellitus； Diabetic Complications； Anti-Inflammatory； Antioxidant； Mechanism
摘要: 糖尿病是一种以慢性高血糖为特征的代谢性疾病，其并发症(如糖尿病肾病、糖尿病视网膜病变、糖尿病心肌病、糖尿病神经病变、糖尿病病足等)是导致患者生活质量下降和死亡的主要原因。芍药苷是从传统中药芍药中提取的单萜苷类化合物，具有抗炎、抗氧化、调节免疫、修复线粒体功能、改善糖脂代谢紊乱和促进血管/组织修复等多种药理作用。近年来，大量研究表明芍药苷对糖尿病及其并发症具有显著的治疗作用，其机制涉及多靶点、多通路调控。本文综述了芍药苷在糖尿病及其主要并发症中的治疗作用及潜在机制，为临床应用和药物开发提供参考。
Abstract: Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. Its complications—such as diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic neuropathy, and diabetic foot—are the primary contributors to reduced quality of life and increased mortality among patients. Paeoniflorin, a monoterpene glycoside extracted from the traditional Chinese medicinal herb Paeonia lactiflora, exhibits a wide range of pharmacological activities, including anti-inflammatory and antioxidant effects, immune modulation, mitochondrial function restoration, improvement of glucose and lipid metabolism, and promotion of vascular and tissue repair. Accumulating evidence in recent years indicates that paeoniflorin exerts significant therapeutic effects on diabetes and its complications through multi-target and multi-pathway mechanisms. This review summarizes the current findings regarding the therapeutic potential and underlying mechanisms of paeoniflorin in relation to diabetes and its major complications, aiming to provide insights for its clinical application and further pharmaceutical development.
文章引用：杨云姣, 陈秋. 芍药苷治疗糖尿病及其并发症研究机制进展[J]. 中医学, 2025, 14(8): 3376-3382. https://doi.org/10.12677/tcm.2025.148499

参考文献

[1] Jia, W., Chan, J.C., Wong, T.Y. and Fisher, E.B. (2025) Diabetes in China: Epidemiology, Pathophysiology and Multi-omics. Nature Metabolism, 7, 16-34. [Google Scholar] [CrossRef] [PubMed]
[2] Yu, W. and Jiang, H. (2024) Paeoniflorin Alleviates High Glucose-Induced Endothelial Cell Apoptosis in Diabetes Mellitus by Inhibiting HRAS-Activated RAS Pathway. Endocrine Journal, 71, 1045-1053. [Google Scholar] [CrossRef] [PubMed]
[3] 何瑞娟, 白露, 谭攀攀, 等. 芍药苷通过调控Akt/FoxO1信号通路对2型糖尿病大鼠的保护作用[J]. 中成药, 2023, 45(8): 2732-2736.
[4] 朱晏伯, 李潇, 朱笳悦, 等. 芍药苷对高糖环境下雪旺细胞线粒体动力学的影响[J]. 中国糖尿病杂志, 2022, 30(3): 214-220.
[5] 杨育辉, 刘华桢, 邓晓冬, 等. 芍药苷对1型糖尿病小鼠的治疗作用及机制研究[J]. 中药材, 2020, 43(8): 2007-2011.
[6] Huang, Y., Wang, J., Yang, L., Yue, L., Zhang, L., Zhang, Y., et al. (2020) Paeoniflorin Ameliorates Glycemic Variability-Induced Oxidative Stress and Platelet Activation in HUVECs and DM Rats. RSC Advances, 10, 42605-42612. [Google Scholar] [CrossRef] [PubMed]
[7] 刘桂英, 牛丽, 常雪允, 等. 芍药苷对妊娠期糖尿病大鼠糖代谢、炎症、氧化应激的改善作用及机制[J]. 中国药房, 2024, 35(12): 1476-1481.
[8] 李新玉, 邵云侠, 王坤, 等. 芍药苷减轻糖尿病小鼠肾组织炎症与JAK2/STAT3信号通路的关系[J]. 安徽医科大学学报, 2018, 53(7): 1026-1032.
[9] Li, X., Wang, Y., Wang, K. and Wu, Y. (2018) Renal Protective Effect of Paeoniflorin by Inhibition of JAK2/STAT3 Signaling Pathway in Diabetic Mice. BioScience Trends, 12, 168-176. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, X., Pang, Y., Bo, Q., Hu, S., Xiang, J., Yang, Z., et al. (2023) Protective Effect of Paeoniflorin in Diabetic Nephropathy: A Preclinical Systematic Review Revealing the Mechanism of Action. PLOS ONE, 18, e0282275. [Google Scholar] [CrossRef] [PubMed]
[11] 赵洪霄, 李英, 张金颖, 等. 芍药苷对糖尿病肾病模型大鼠肾脏的保护作用及作用机制[J]. 中国药业, 2022, 31(3): 31-35.
[12] 段分分, 杨雯雯, 邵云侠, 等. 芍药苷对糖尿病小鼠肾组织中TLR2信号通路的调节作用[J]. 安徽医科大学学报, 2018, 53(8): 1252-1259.
[13] Shao, Y., Xu, X., Wang, K., Qi, X. and Wu, Y. (2017) Paeoniflorin Attenuates Incipient Diabetic Nephropathy in Streptozotocin-Induced Mice by the Suppression of the Toll-Like Receptor-2 Signaling Pathway. Drug Design, Development and Therapy, 11, 3221-3233. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, T., Zhu, Q., Shao, Y., Wang, K. and Wu, Y. (2017) Paeoniflorin Prevents TLR2/4-Mediated Inflammation in Type 2 Diabetic Nephropathy. BioScience Trends, 11, 308-318. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, X., Jiang, L., Liu, X., Huang, Y., Wang, A., Zeng, H., et al. (2022) Paeoniflorin Binds to VEGFR2 to Restore Autophagy and Inhibit Apoptosis for Podocyte Protection in Diabetic Kidney Disease through PI3K-AKT Signaling Pathway. Phytomedicine, 106, Article ID: 154400. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, X., Liu, X., Jiang, L., Huang, Y., Zeng, H., Zhu, Q., et al. (2022) Paeoniflorin Directly Binds to TNFR1 to Regulate Podocyte Necroptosis in Diabetic Kidney Disease. Frontiers in Pharmacology, 13, Article 966645. [Google Scholar] [CrossRef] [PubMed]
[17] Qi, X., Guo, H., Xia, X., Liu, Y., Qiu, S., Lin, T., et al. (2025) Paeoniflorin Alleviated STZ-Induced Diabetic Retinopathy via Regulation of the PDI/ADAM17/MerTK Pathway. International Immunopharmacology, 155, Article ID: 114571. [Google Scholar] [CrossRef] [PubMed]
[18] 朱昭亮, 白淑玮, 段鹏, 等. 芍药苷调控PI3K/Akt信号通路对糖尿病视网膜病变大鼠炎症反应的影响[J]. 国际眼科杂志, 2025, 25(3): 365-371.
[19] 刘霞, 易勉, 李灵, 等. 基于HIF-1α通路探讨芍药苷改善糖尿病视网膜病变引起的组织和细胞损伤的机制[J]. 眼科新进展, 2025, 45(3): 196-201.
[20] Sun, W., Wang, R., Gong, K., Wang, L., Li, F. and Deng, J. (2024) Paeoniflorin-Mediated Downregulation of VEGFA: Unveiling the Therapeutic Mechanism of Buyang Huanwu Decoction in Diabetic Retinopathy. Naunyn-Schmiedeberg’s Archives of Pharmacology, 398, 4571-4582. [Google Scholar] [CrossRef] [PubMed]
[21] 张博, 李凤君, 刘学政, 等. 芍药苷基于JAK2/STAT3信号通路抑制糖尿病大鼠视网膜细胞炎症的研究[J]. 中国中医眼科杂志, 2023, 33(4): 305-310.
[22] 张博, 李凤君, 左中夫. 芍药苷对糖尿病大鼠视网膜Müller细胞的保护作用[J]. 中国中医眼科杂志, 2019, 29(1): 5-9.
[23] Wu, H., Zhang, P., Zhou, J., Hu, S., Hao, J., Zhong, Z., et al. (2024) Paeoniflorin Confers Ferroptosis Resistance by Regulating the Gut Microbiota and Its Metabolites in Diabetic Cardiomyopathy. American Journal of Physiology-Cell Physiology, 326, C724-C741. [Google Scholar] [CrossRef] [PubMed]
[24] 李姗姗, 田春雨, 张国伟, 等. 芍药苷对2型糖尿病模型大鼠心肌损伤的改善作用及机制研究[J]. 中国药房, 2021, 32(23): 2846-2853.
[25] Yang, X., Li, X., Zhu, Y., Gao, Y. and Xu, L. (2022) Paeoniflorin Upregulates Mitochondrial Thioredoxin of Schwann Cells to Improve Diabetic Peripheral Neuropathy Indicated by 4D Label‐Free Quantitative Proteomics. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 4775645. [Google Scholar] [CrossRef] [PubMed]
[26] 刘东齐, 闫仕祺, 刘浩龙, 等. 芍药苷对糖尿病周围神经病变状态下线粒体输入途径蛋白TOM20的作用[J]. 中草药, 2024, 55(9): 2987-2995.
[27] 孙晓萌, 李潇, 朱笳悦, 等. 芍药苷调节高糖环境下线粒体相关内质网膜对雪旺细胞凋亡的影响[J]. 环球中医药, 2020, 13(6): 964-969.
[28] 宋思瑶, 陆彭, 伍鼎骁, 等. 基于网络药理学与分子对接探讨芍药苷治疗糖尿病的作用[J]. 中国临床药理学杂志, 2024, 40(15): 2261-2264.
[29] Yadav, J.P., Verma, A., Pathak, P., Dwivedi, A.R., Singh, A.K., Kumar, P., et al. (2024) Phytoconstituents as Modulators of NF-κB Signalling: Investigating Therapeutic Potential for Diabetic Wound Healing. Biomedicine & Pharmacotherapy, 177, Article ID: 117058. [Google Scholar] [CrossRef] [PubMed]
[30] Jia, X., Dou, Z., Zhang, Y., Yu, C., Yang, M., Xie, H., et al. (2025) Application of a Novel Thermal/pH-Responsive Antibacterial Paeoniflorin Hydrogel Crosslinked with Amino Acids for Accelerated Diabetic Foot Ulcers Healing. Materials Today Bio, 32, Article ID: 101736. [Google Scholar] [CrossRef] [PubMed]
[31] Yu, H., Gong, W., Mei, J., Qin, L., Piao, Z., You, D., et al. (2022) The Efficacy of a Paeoniflorin-Sodium Alginate-Gelatin Skin Scaffold for the Treatment of Diabetic Wound: An in Vivo Study in a Rat Model. Biomedicine & Pharmacotherapy, 151, Article ID: 113165. [Google Scholar] [CrossRef] [PubMed]
[32] Yang, H., Song, L., Sun, B., Chu, D., Yang, L., Li, M., et al. (2021) Modulation of Macrophages by a Paeoniflorin-Loaded Hyaluronic Acid-Based Hydrogel Promotes Diabetic Wound Healing. Materials Today Bio, 12, Article ID: 100139. [Google Scholar] [CrossRef] [PubMed]
[33] Sun, X., Wang, X., Zhao, Z., Chen, J., Li, C. and Zhao, G. (2020) Paeoniflorin Inhibited Nod‐Like Receptor Protein‐3 Inflammasome and NF‐κB‐Mediated Inflammatory Reactions in Diabetic Foot Ulcer by Inhibiting the Chemokine Receptor CXCR2. Drug Development Research, 82, 404-411. [Google Scholar] [CrossRef] [PubMed]
[34] 房志锐, 陈璐, 李春晓, 等. 芍药苷促进糖尿病创面愈合[J]. 中国药理学通报, 2019, 35(8): 1084-1091.
[35] Sun, X., Wang, X., Zhao, Z., Chen, J., Li, C. and Zhao, G. (2020) Paeoniflorin Accelerates Foot Wound Healing in Diabetic Rats Though Activating the NRF2 Pathway. Acta Histochemica, 122, Article ID: 151649. [Google Scholar] [CrossRef] [PubMed]
[36] Yuan, C.k., Gao, Y., Yu, J. and Peng, L. (2024) Protective Effects of Paeoniflorin against Inflammation and Oxidative Stress in Rats with Gestational Diabetes Mellitus via Inhibiting the Rhoa/Rock Signaling Pathway. Revista Brasileira de Farmacognosia, 34, 536-552. [Google Scholar] [CrossRef] 
[37] Zhang, Y., Liang, Y., Liu, H., Huang, Y., Li, H. and Chen, B. (2020) Paeoniflorin Attenuates Gestational Diabetes via Akt/mTOR Pathway in a Rat Model. Food & Nutrition Research, 64, Article 4362. [Google Scholar] [CrossRef] [PubMed]
[38] 王露蓉, 陈磊, 胡小平. 芍药苷对糖尿病肝损伤GK大鼠模型的机制研究[J]. 中国动物保健, 2025, 27(3): 216-218.
[39] Wang, A., Gong, Y., Pei, Z., Jiang, L., Xia, L. and Wu, Y. (2022) Paeoniflorin Ameliorates Diabetic Liver Injury by Targeting the TXNIP-Mediated NLRP3 Inflammasome in db/db Mice. International Immunopharmacology, 109, Article ID: 108792. [Google Scholar] [CrossRef] [PubMed]
[40] 王安丽, 朱启金, 吴永贵, 等. 芍药苷抑制NLRP3炎症小体通路对db/db小鼠肝脏炎症和纤维化的影响[J]. 安徽医科大学学报, 2022, 57(11): 1687-1693.